drugset / Trial / NCT04952064
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
Phase 4
Completed
300 enrolled
General Hospital of Shenyang Military Region
The Third Xiangya Hospital of Central South University · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.
Timeline
- Start
- 2021-07-28
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monosialoganglioside GM1 | Unknown | 200 mg | — |
| Subject | Monosialoganglioside GM1 | Unknown | 400 mg | — |